Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (118)	1/8/2002 8:17:07 PM
From: SemiBull	Read Replies (1) \| Respond to of 222

5:32PM Corixa Corp (CRXA) 14.83 -0.76: Company announces positive trial data; saw highly statistically significant preliminary results of an ongoing Phase III trial of the company's RC-529 synthetic adjuvant when used in combination with Rhein Biotech's yeast Hansenula; results of the primary efficacy analyses showed that there were significantly more patients seroprotected after two immunizations with Rhein Biotech's Hepatitis B vaccine plus RC-529 than with the Hepatitis B vaccine alone (95.5% vs. 82.1%).